Choreo LLC Has $588,000 Stock Position in Unum Group (NYSE:UNM)

Choreo LLC cut its holdings in shares of Unum Group (NYSE:UNM) by 19.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,056 shares of the financial services provider’s stock after selling 1,929 shares during the period. Choreo LLC’s holdings in Unum Group were worth $588,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of UNM. Versant Capital Management Inc lifted its holdings in Unum Group by 26.4% in the fourth quarter. Versant Capital Management Inc now owns 766 shares of the financial services provider’s stock valued at $56,000 after buying an additional 160 shares during the period. Thurston Springer Miller Herd & Titak Inc. lifted its stake in shares of Unum Group by 28.8% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 800 shares of the financial services provider’s stock valued at $58,000 after purchasing an additional 179 shares during the period. CIBC Asset Management Inc lifted its stake in shares of Unum Group by 3.4% in the 3rd quarter. CIBC Asset Management Inc now owns 5,551 shares of the financial services provider’s stock valued at $330,000 after purchasing an additional 180 shares during the period. V Square Quantitative Management LLC boosted its position in shares of Unum Group by 38.2% in the 3rd quarter. V Square Quantitative Management LLC now owns 702 shares of the financial services provider’s stock worth $42,000 after purchasing an additional 194 shares during the last quarter. Finally, Brooklyn Investment Group grew its stake in shares of Unum Group by 3.1% during the third quarter. Brooklyn Investment Group now owns 6,592 shares of the financial services provider’s stock worth $392,000 after purchasing an additional 197 shares during the period. Institutional investors own 86.57% of the company’s stock.

Insider Buying and Selling

In other news, EVP Lisa G. Iglesias sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $72.61, for a total value of $363,050.00. Following the completion of the sale, the executive vice president now owns 35,840 shares of the company’s stock, valued at approximately $2,602,342.40. This represents a 12.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Hanley Ronald P. O sold 14,299 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $72.10, for a total transaction of $1,030,957.90. Following the transaction, the director now owns 38,819 shares in the company, valued at approximately $2,798,849.90. The trade was a 26.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 98,164 shares of company stock worth $7,346,040. 0.93% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on UNM shares. Piper Sandler increased their target price on Unum Group from $82.00 to $87.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Truist Financial increased their price target on shares of Unum Group from $70.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. restated a “neutral” rating and set a $79.00 price objective (up previously from $74.00) on shares of Unum Group in a report on Tuesday, January 7th. Morgan Stanley increased their target price on shares of Unum Group from $62.00 to $64.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. Finally, BMO Capital Markets assumed coverage on shares of Unum Group in a report on Thursday, January 23rd. They issued an “outperform” rating and a $91.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $79.45.

Unum Group Price Performance

UNM stock opened at $75.24 on Wednesday. The stock has a 50-day moving average price of $74.21 and a two-hundred day moving average price of $65.80. Unum Group has a 1 year low of $47.65 and a 1 year high of $79.43. The stock has a market cap of $13.74 billion, a PE ratio of 7.94, a price-to-earnings-growth ratio of 1.17 and a beta of 0.80. The company has a current ratio of 0.29, a quick ratio of 0.28 and a debt-to-equity ratio of 0.32.

Unum Group (NYSE:UNM) last posted its quarterly earnings data on Tuesday, February 4th. The financial services provider reported $2.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.14 by ($0.11). Unum Group had a return on equity of 14.91% and a net margin of 13.81%. Equities analysts forecast that Unum Group will post 9.12 EPS for the current fiscal year.

Unum Group Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Friday, January 24th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 2.23%. The ex-dividend date is Friday, January 24th. Unum Group’s dividend payout ratio is presently 17.74%.

About Unum Group

Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, Poland, and internationally. It operates through Unum US, Unum International, Colonial Life, and Closed Block segment. The company offers group long-term and short-term disability, group life, and accidental death and dismemberment products; supplemental and voluntary products, such as individual disability, voluntary benefits, and dental and vision products; and accident, sickness, disability, life, and cancer and critical illness products.